Estrella CFO exercises 100K stock options at $0.815

Estrella Immunopharma, Inc. (ESLA) reported that its Chief Financial Officer, Jiandong Xu, exercised 100,000 Incentive Share Options on 2026-08-18 at an exercise price of $0.815 per share, receiving an equal number of common shares.

Rhea-AI Filing Summary

Estrella Immunopharma, Inc. (ESLA) reported that its Chief Financial Officer, Jiandong Xu, exercised 100,000 Incentive Share Options on 2026-08-18 at an exercise price of $0.815 per share, receiving an equal number of common shares. Following the exercise, Xu directly holds 365,488 shares of common stock and 390,796 incentive share options. The options exercised were granted on 2024-10-30 under the 2023 Omnibus Incentive Plan and were vested as to the shares exercised.

Insider Trade Summary

100,000 shares exercised/converted

Exercise 2 txns

Insider Xu Jiandong

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Incentive Share Option F3, F4	100,000	--	--
Exercise	Common Stock, par value $0.0001 per share F1, F2	100,000	$0.815	$82K

Holdings After Transaction: Incentive Share Option — 390,796 contracts (Direct); Common Stock, par value $0.0001 per share — 365,488 shares (Direct)

Footnotes (4)

1. F1. Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.
2. F2. Reflects the 265,488 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.
3. F3. Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.
4. F4. Not applicable - the reported transaction is the exercise of the stock option for the exercise price set forth in Column 2; no separate consideration was paid or received for the derivative security.

Key Figures

Options exercised: 100,000 shares Exercise price per share: $0.815 per share Common stock holdings after transaction: 365,488 shares +5 more

8 metrics

Options exercised 100,000 shares Incentive Share Options exercised on 2026-08-18

Exercise price per share $0.815 per share Exercise price for Incentive Share Options

Common stock holdings after transaction 365,488 shares Directly owned by Jiandong Xu after exercise

Option holdings after transaction 390,796 options Incentive Share Options remaining after exercise

Option grant date 2024-10-30 Grant date of Incentive Share Options under 2023 Omnibus Incentive Plan

Option expiration date 2034-10-29 Expiration of Incentive Share Options exercised

Immediate vesting portion 25% Portion of award immediately exercisable on grant date

Monthly vesting installments 1/48th per month Remaining options vest monthly after 2024-10-30

Key Terms

Incentive Share Option, 2023 Omnibus Incentive Plan, exercise price, vested

4 terms

Incentive Share Option financial

"Represents incentive share options granted to the Reporting Person on October 30, 2024"

2023 Omnibus Incentive Plan financial

"granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan"

exercise price financial

"Represents the exercise price per share paid by the Reporting Person upon the exercise"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"The options were vested as to the shares exercised"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ESLA CFO Jiandong Xu report on this Form 4?

Jiandong Xu reported exercising 100,000 Incentive Share Options on 2026-08-18, converting them into 100,000 shares of common stock of Estrella Immunopharma, Inc.

At what price were Jiandong Xu’s ESLA stock options exercised?

The options were exercised at an exercise price of $0.815 per share, which represents the price paid by Jiandong Xu upon the exercise of the stock options.

How many ESLA common shares does Jiandong Xu own after this transaction?

After the reported exercise, Jiandong Xu directly owns 365,488 shares of common stock of Estrella Immunopharma, Inc., reflecting 265,488 shares previously held plus 100,000 shares acquired in this transaction.

How many ESLA options does Jiandong Xu hold after exercising 100,000 Incentive Share Options?

Following the transaction, Jiandong Xu holds 390,796 Incentive Share Options, as reported in the derivative securities table for Estrella Immunopharma, Inc.

When were the ESLA Incentive Share Options granted to Jiandong Xu and how do they vest?

The Incentive Share Options were granted on 2024-10-30 under the 2023 Omnibus Incentive Plan. 25% was immediately exercisable on the grant date, with the remaining 75% vesting in equal 1/48th monthly installments after 2024-10-30.

Did Jiandong Xu pay any additional consideration for the ESLA derivative security itself?

No. The filing states that no separate consideration was paid or received for the derivative security; only the $0.815 per share exercise price was paid upon exercising the stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 09:56 PM Accepted by SEC EDGAR 08/25/2026 - 09:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Jiandong

(Last) (First) (Middle)

C/O ESTRELLA IMMUNOPHARMA, INC.

5858 HORTON STREET, SUITE 370

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Estrella Immunopharma, Inc. [ ESLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/18/2026		M		100,000	A	$0.815(1)	365,488(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Share Option(3)	$0.815	08/18/2026		M			100,000	10/31/2024(3)	10/29/2034	Common Stock	100,000	(4)	390,796	D

Explanation of Responses:

1. Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.

2. Reflects the 265,488 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.

3. Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.

4. Not applicable - the reported transaction is the exercise of the stock option for the exercise price set forth in Column 2; no separate consideration was paid or received for the derivative security.

	/s/ Jiandong Xu	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)